title: Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer.
abstract: Ten patients with metastatic breast cancer were treated with a combination of recombinant alpha-interferon and recombinant interleukin-2. The toxicity of treatment was considerable, including one death on therapy. No objective responses were seen.
authors.affiliation: Department of Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030-4009.
authors.forename: R S
authors.initials: RS
authors.lastname: Walters
authors.forename: R L
authors.initials: RL
authors.lastname: Theriault
authors.forename: F A
authors.initials: FA
authors.lastname: Holmes
authors.forename: L
authors.initials: L
authors.lastname: Esparza
authors.forename: G N
authors.initials: GN
authors.lastname: Hortobagyi
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000556:secondary* / Q000628:therapy*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins